EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata

Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss. Severe AA, defined as >50% score on the Severity of Alopecia Tool (SALT), is prevalent in 0.04-0.09% of the US population. Corticosteroids, minoxidil, and immunomodulators are used to treat AA; however, there are no FDA-approved therapies. Baricitinib is an oral Janus kinase inhibitor being investigated for treating severe AA. The budget impact of adding baricitinib to a commercial formulary for severe AA treatment was estimated from a US payer perspective.